NCT03626818: The Impact of Neurocognitive Function in Patients With Multiple Brain Metastases Receiving Whole Brain Radiation Therapy

NCT03626818
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Not Applicable
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have at least 3 metastatic lesions in the brain
Exclusions: Patients with confirmed metastases in the spinal cord or meninges; Prior radiation therapy to the brain
https://ClinicalTrials.gov/show/NCT03626818

Comments are closed.

Up ↑